Metagenomi (MGX) Competitors $1.54 +0.06 (+3.69%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. ZYBT, ESPR, DBVT, MDWD, YMAB, TIL, SLRN, IMAB, DSGN, and SCPHShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Zhengye Biotechnology (ZYBT), Esperion Therapeutics (ESPR), DBV Technologies (DBVT), MediWound (MDWD), Y-mAbs Therapeutics (YMAB), Instil Bio (TIL), Acelyrin (SLRN), I-Mab (IMAB), Design Therapeutics (DSGN), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Zhengye Biotechnology Esperion Therapeutics DBV Technologies MediWound Y-mAbs Therapeutics Instil Bio Acelyrin I-Mab Design Therapeutics scPharmaceuticals Zhengye Biotechnology (NASDAQ:ZYBT) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Do analysts rate ZYBT or MGX? Metagenomi has a consensus price target of $13.00, indicating a potential upside of 741.42%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer ZYBT or MGX? Metagenomi received 23 more outperform votes than Zhengye Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformZhengye BiotechnologyN/AN/AMetagenomiOutperform Votes2392.00% Underperform Votes28.00% Does the media favor ZYBT or MGX? In the previous week, Metagenomi had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 7 mentions for Metagenomi and 3 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.62 beat Metagenomi's score of 0.45 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ZYBT or MGX more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Zhengye Biotechnology's return on equity of 0.00% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Zhengye BiotechnologyN/A N/A N/A Metagenomi -134.27%-43.23%-18.86% Which has higher earnings and valuation, ZYBT or MGX? Zhengye Biotechnology has higher revenue and earnings than Metagenomi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZhengye Biotechnology$189.75M1.81N/AN/AN/AMetagenomi$45.26M1.28-$68.25M-$2.11-0.73 SummaryZhengye Biotechnology beats Metagenomi on 6 of the 11 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.75M$3.09B$5.57B$8.62BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-0.7333.3227.1420.06Price / Sales1.28469.84419.32157.08Price / CashN/A168.6838.2534.64Price / BookN/A3.457.064.70Net Income-$68.25M-$72.35M$3.23B$247.88M7 Day Performance-6.93%6.23%2.83%2.63%1 Month Performance-0.32%16.53%9.02%6.36%1 Year Performance-74.46%-16.90%31.36%14.05% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi2.3047 of 5 stars$1.55+3.7%$13.00+741.4%-76.8%$57.75M$45.26M-0.73236Positive NewsZYBTZhengye BiotechnologyN/A$5.16-12.7%N/AN/A$243.38M$189.75M0.00278Gap UpESPREsperion Therapeutics4.1016 of 5 stars$1.20-1.6%$6.25+420.8%-58.3%$237.84M$259.57M-1.88200Options VolumeAnalyst RevisionDBVTDBV Technologies3.4463 of 5 stars$8.68-4.9%$14.75+69.9%+72.7%$237.75M$15.73M-1.9380News CoverageMDWDMediWound1.7844 of 5 stars$21.46-0.6%$31.80+48.2%+26.0%$231.94M$19.21M-7.4080YMABY-mAbs Therapeutics3.7663 of 5 stars$5.08-3.6%$15.60+207.1%-59.0%$230.04M$88.66M-9.41150Positive NewsAnalyst RevisionTILInstil Bio2.6619 of 5 stars$35.07+6.6%$119.00+239.3%+237.3%$230.02MN/A-3.03410Short Interest ↑High Trading VolumeSLRNAcelyrin2.9816 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135Positive NewsIMABI-Mab3.2194 of 5 stars$2.80+14.3%$5.50+96.4%+33.9%$228.65M$3.27M0.00380News CoveragePositive NewsGap UpHigh Trading VolumeDSGNDesign Therapeutics0.6553 of 5 stars$3.91-2.5%$4.00+2.3%-3.2%$227.64MN/A-4.6040Positive NewsSCPHscPharmaceuticals4.4331 of 5 stars$4.25+1.2%$14.00+229.4%-0.7%$224.37M$41.98M-2.2430Positive News Related Companies and Tools Related Companies Zhengye Biotechnology Competitors Esperion Therapeutics Competitors DBV Technologies Competitors MediWound Competitors Y-mAbs Therapeutics Competitors Instil Bio Competitors Acelyrin Competitors I-Mab Competitors Design Therapeutics Competitors scPharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGX Stock Free MGX Stock Alerts